Advertisement

Topics

Ocugen’s treatment for ocular graft-versus-host disease gets orphan drug designation

10:13 EDT 9 Aug 2017 | Healio

The FDA has granted orphan drug designation for OCU300 to treat ocular graft-versus-host disease, according to a press release from Ocugen. Ocular graft-versus-host disease affects 40% to 60% of patients who have undergone allergenic hematological stem cell or bone marrow transplants, and it induces severe ocular surface disease, the release said.

Original Article: Ocugen’s treatment for ocular graft-versus-host disease gets orphan drug designation

NEXT ARTICLE

More From BioPortfolio on "Ocugen’s treatment for ocular graft-versus-host disease gets orphan drug designation"

Quick Search
Advertisement
 

Relevant Topic

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...